For Investors

Corporate Profile
AVEO Oncology is a biopharmaceutical company committed to discovering and developing targeted therapies designed to provide substantial impact in the lives of people with cancer by addressing unmet medical needs. AVEO’s proprietary Human Response Platform provides the company unique insights into cancer and related disease biology and is being leveraged in the discovery and clinical development of its therapeutic candidates.
Stock Quote
AVEO (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Up 0.10 (14.08%)
Data as of 12/18/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent Press Releases 
11/11/14AVEO Enters into Research and Exclusive Option Agreement with Ophthotech for Tivozanib (VEGF inhibitor) for the Treatment of Ocular Diseases
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 11, 2014-- AVEO Oncology (NASDAQ:AVEO) today announced that it has entered into a research and exclusive option agreement with Ophthotech Corporation, under which it has provided Ophthotech an exclusive license to investigate the potential of AVEO’s small molecule vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor, tivozanib, outside of Asia for the potential treatment of non-oncologic diseases of ... 
Printer Friendly Version
11/05/14AVEO Oncology Reports Third Quarter 2014 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 5, 2014-- AVEO Oncology (NASDAQ:AVEO) today reported its third quarter 2014 financial results and provided an overview of its progress toward achieving its strategic plan. “At AVEO, we continue to execute on all aspects of our strategic plan. We are focused on the progression of AV-380 in cancer cachexia toward an IND application filing next year, while remaining opportunistic to leveraging partner r... 
Printer Friendly Version
09/29/14AVEO Oncology Announces Results from Phase 2 Clinical Studies of Tivozanib in Patients with Advanced Colorectal and Kidney Cancers Presented at ESMO 2014 Congress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 29, 2014-- AVEO Oncology (NASDAQ:AVEO) today announced poster presentations for two Phase 2 clinical studies of tivozanib, one in metastatic colorectal cancer (mCRC) and one in renal cell carcinoma (RCC), at the 2014 Congress of the European Society for Medical Oncology (ESMO), taking place September 25–30 in Madrid, Spain. Tivozanib is an oral, potent, selective inhibitor of vascular endothelial growth factor tyro... 
Printer Friendly Version
More Press Releases >>
Upcoming Events 
There are currently no events scheduled.
More Events >>
Phase 2 clinical evaluation of preclinically defined biomarkers for vascular endothelial growth factor tyrosine kinase inhibitor tivozanib in renal cell carcinoma
BATON-CRC: a phase 2 randomized trial comparing tivozanib + mFOLFOX6 with bevacizumab + mFOLFOX6 in stage IV metastatic colorectal cancer
Efficacy analysis of gefitinib +/- ficlatuzumab in serum proteomic-based subgroups of patients with previously untreated lung adenocarcinoma
First in human Phase 1 dose-escalation study of AV-203; #395, J. Sarantopoulos
AACR 2014, Cancer Cachexia Poster #1441, Liu
More Presentations >>

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.